Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,304
datasets available to search
ShareScore release 0.9.0
Dataset results
1,304 results for “Cognitive impairments”
Exploring Feasibility, Acceptability and Impact of Using Neurofeedback with Persons with Mild Cognitive Impairment
ClinicalTrials.gov study NCT06762522. IPD Sharing: NO. Countries: 1. Publications: 12.
Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment
ClinicalTrials.gov study NCT05498493. IPD Sharing: YES. Countries: 1. Publications: 1.
The Effect of Electroacupuncture Treatment on Cognitive Function in Adults With Amnestic Mild Cognitive Impairment
ClinicalTrials.gov study NCT06626828. IPD Sharing: YES. Countries: 1. Publications: 4.
Cognitive Impairment in Atrial Fibrillation
ClinicalTrials.gov study NCT01816308. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment
ClinicalTrials.gov study NCT04109963. IPD Sharing: YES. Countries: 1. Publications: 1.
The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment
ClinicalTrials.gov study NCT02590874. IPD Sharing: NO. Countries: 1. Publications: 5.
Treating Insomnia in Mild Cognitive Impairment
ClinicalTrials.gov study NCT06687161. IPD Sharing: YES. Countries: 1. Publications: 0.
P300 in Early Cognitive Impairment in Hepatitis C Virus
ClinicalTrials.gov study NCT04389268. IPD Sharing: NO. Countries: 1. Publications: 5.
Personalized Virtual Reality Naturalistic Scenarios in Cognitive Impairment
ClinicalTrials.gov study NCT05863065. IPD Sharing: NO. Countries: 1. Publications: 1.
Functional and Cognitive Impairment Prevention for Elderly Hospitalized Patients
ClinicalTrials.gov study NCT02300896. IPD Sharing: Not stated. Countries: 1. Publications: 8.
The Effects of Transcranial Direct Current Stimulation in Mild Cognitive Impairment
ClinicalTrials.gov study NCT03441152. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Frequency of biologically-defined AD in relation to age, sex, APOEε4 and cognitive impairment in a prospective cohort study
Open the record for dataset details and reuse information.
Metabolites of intestinal fora can be used as diagnostic and progressive markers for mild cognitive impairment
Open the record for dataset details and reuse information.
Data file for Rainer M & Mucke H, Acutil in mild cognitive impairment or early dementia: an exploratory observational pilot study
<p>Legend:to column headers:</p> <p><strong>Random No.:</strong> Participant randomization code<br> <strong>ChEI:</strong> Cholinesterase inhibitor as background therapy?<br> <strong>V(x)_Date:</strong> Date of sequential patient visits (x = 1-6 and EOT = end of therapy)<br> <strong>V(x)_CDR</strong>: Clinical Dementia Rating Scale - Sum of Boxes at respective visit<br> <strong>V(x)_ADAS:</strong> Alzheimer Diseases Assessment Scale cognitive subscale at respective visit<br> <strong>V(x)_COWAT: </strong>Controlled Oral Word Association Test score at respective visit<br> <strong>V(x)_MMSE:</strong> Mini-Mental State Exam at respective visit<br> </p>
Data from: Distinct association between APOE ε2 and Aβ in Alzheimer- and vascular-type cognitive impairment
<p><b>Objective:</b> To investigate the association between apolipoprotein E<i> </i>(<i>APOE</i>) genotype and amyloid-β (Aβ) burden, as measured by PET in patients with subcortical vascular cognitive impairment (SVCI) and those with Alzheimer's disease-related cognitive impairment (ADCI).</p> <p><b>Methods:</b> This was a cross-sectional study of 310 patients with SVCI and 999 with ADCI. To evaluate the effects of <i>APOE</i> genotype or diagnostic group on Aβ-positivity, we performed multivariate logistic regression analyses. Further distinctive underlying features of latent subgroups were examined by employing a latent class cluster analysis approach.</p> <p><b>Results: </b>In comparison with ε3 homozygotes, in the ADCI group, ε2 carriers showed a lower frequency of Aβ-positivity (odds ratio [OR] 0.43, 95% CI 0.23–0.79) while in the SVCI group, ε2 carriers showed a higher frequency of Aβ-positivity (OR 2.26, 95% CI 1.02–5.01). In particular, we observed an interaction effect of ε2 carrier status and diagnostic group on Aβ-positivity (OR 5.12, 95% CI 1.93–13.56), in that relative to ε3 homozygotes, there were more Aβ-positive ε2 carriers in the SVCI group than in the ADCI group. We also identified latent subgroups of Aβ-positive <i>APOE</i> ε2 carriers with SVCI and Aβ-positive <i>APOE</i> ε4 carriers with ADCI.</p> <p><b>Conclusions: </b>Our findings suggest that <i>APOE</i> ε2 shows distinctly associated with Aβ deposition in patients with SVCI and those with ADCI. Our findings further suggest that there is a distinctive subgroup of Aβ-positive <i>APOE</i> ε2 carriers with SVCI among patients with cognitive impairments.</p>
Is metformin the only culprit for cognitive impairment in diabetes?
<p><strong>Background</strong></p> <p><span>As diabetic patients conventionally are on a long-term prescription for metformin, it is important to identify any increase in their risk for developing cognitive disorders. Hence, an attempt was made here to study cognitive impairment by using the Montreal Cognitive Assessment test (MoCA) as a possible predictor of development of cognitive impairment in type 2 diabetics on metformin therapy.</span></p> <p><strong>Methods</strong></p> <p>400 Type 2 diabetics on metformin-containing anti-diabetic regimen were enrolled and data recorded. A cognitive test, MoCA, was administered and a score of less than 26 was considered abnormal. </p> <p><strong>Results</strong></p> <p><span>In this study, the participants on metformin had a </span>statistically significant correlation with age > 65 years, duration of diabetes (>5 years), metformin dose (1 gm and more) and presence of diabetes complications. Ordinal regressions showed significant correlation between abnormal MoCA scores and older age, longer duration of DM, and presence of one of the DM complications.</p> <p><strong>Conclusions</strong></p> <p>Amongst patients receiving medical therapy for control of type 2 diabetes, participants using metformin showed a very high prevalence rate of abnormal MoCA scores (85%). Increased duration of metformin intake leads to a decline in MoCA performance.</p>
Dataset_Cognitive impairment and depressive symptoms
<p>This is the dataset used to analyse data. </p>
Online Meditation for Mild Cognitive Impairment and Mild Dementia
ClinicalTrials.gov study NCT06768450. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.
Patient Priorities Care Among Persons Living With Mild Cognitive Impairment and Dementia
ClinicalTrials.gov study NCT06001775. IPD Sharing: NO. Countries: 1. Publications: 0.
Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia
ClinicalTrials.gov study NCT05078437. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.